Mode
Text Size
Log in / Sign up

Psychotherapy and pharmacotherapy for anxiety disorders involve distinct neural pathways and large symptom reductionsPsychotherapy and medication affect different brain regions in anxiety

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that psychotherapy and pharmacotherapy for anxiety may engage distinct neural pathways and show large symptom reductions.

This meta-analysis examined the neural correlates of treatment for anxiety disorders in 561 patients. The study compared the effects of psychotherapy versus pharmacotherapy on pre- and post-treatment whole-brain coordinates using fMRI. The primary outcome was the identification of distinct neural pathways associated with each treatment modality.

Findings indicated a large pooled reduction in primary anxiety symptoms (Hedges' g = 1.44; 95% CI 0.99-1.90). Regarding neural activity, psychotherapy was associated with decreased activation in prefrontal and striatal regions, including the medial, middle, and inferior frontal gyri and caudate nucleus. In contrast, pharmacotherapy was associated with focal decreases in the right uncus. These results suggest that the two modalities may engage partly distinct neural pathways, with psychotherapy involving broader prefrontal-striatal modulation and pharmacotherapy showing more focal limbic effects.

The authors note that the evidence base is limited and heterogeneous. Because the results are derived from an ALE meta-analysis of task-based fMRI, the findings are exploratory. Clinical application of these results should be interpreted with caution due to the exploratory nature of the data and the heterogeneity of the included studies.

Living with anxiety can feel like your brain is stuck in a constant state of alarm. While both talk therapy and medication are common ways to treat it, we are still learning about how these treatments actually change the way the brain functions.

Researchers looked at brain scans from 561 patients with anxiety disorders. They found that talk therapy and medication might work through different pathways. Specifically, talk therapy showed broader changes in the prefrontal and striatal regions of the brain. In contrast, medication showed more focused changes in the limbic system, specifically in an area called the right uncus.

Both methods led to a large reduction in primary anxiety symptoms. However, because the evidence used in this study was limited and varied, these findings are still considered exploratory. This means while the results are interesting, more research is needed to fully understand these brain patterns.

What this means for you:
Talk therapy and medication may treat anxiety by affecting different areas of the brain.

Common questions

How do talk therapy and medication differ in how they affect the brain?

The study suggests they may engage different neural pathways. Talk therapy showed broader changes in the prefrontal and striatal regions. Medication showed more focused effects in the limbic system, specifically in the right uncus. Both methods were shown to significantly reduce primary anxiety symptoms.

Is this finding a sure way to choose between therapy and medicine?

Because the evidence base is limited and varied, these results are considered exploratory. The study shows a link between treatment types and brain activity, but it does not provide a definitive rule for choosing one treatment over the other. You should talk to your doctor about the best plan for you.

Study Details

Study typeMeta analysis
Sample sizen = 561
EvidenceLevel 1
PublishedDec 2026
View Original Abstract ↓
BACKGROUND: Anxiety disorders (ADs) involve dysregulation of prefrontal-limbic circuits, but the neural effects of psychotherapy and pharmacotherapy remain unclear. METHODS: We conducted an activation likelihood estimation (ALE) meta-analysis of task-based fMRI studies reporting pre- and post-treatment whole-brain coordinates in ADs. Separate analyses were performed for psychotherapy and pharmacotherapy. A random-effects synthesis assessed changes in primary anxiety symptoms where extractable data were available. RESULTS: 27 studies involving 561 patients were included. Psychotherapy was associated mainly with decreased activation in prefrontal and striatal regions, including the medial, middle, and inferior frontal gyri and caudate nucleus, whereas pharmacotherapy showed more focal decreases in the right uncus. Subgroup analyses suggested heterogeneity across therapies, diagnoses, and tasks. 9 independent active-treatment cohorts (179 participants) showed a large pooled symptom reduction (Hedges' g = 1.44, 95% CI 0.99-1.90; I² = 75.1%). CONCLUSIONS: Psychotherapy and pharmacotherapy may engage partly distinct neural pathways in ADs, with broader prefrontal-striatal modulation after psychotherapy and more focal limbic effects after pharmacotherapy. Findings remain exploratory given the limited and heterogeneous evidence base.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.